Incyte Reports $1.56 Billion Third-Quarter Revenue and Raises 2026 Sales Guidance
Article excerpt
Highlighted: the sentence this signal was extracted from
Incyte (INCY) reported third-quarter 2026 total GAAP revenue of $1.56 billion, up 14% from a year earlier. The company posted a GAAP net loss of $784.8 million, or $3.86 per basic and diluted share, driven in part by a $1.23 billion in-process research and development expense related to its Vega Therapeutics acquisition. Total net sales rose 14% to $1.32 billion. Incyte raised its 2026 guidance for total net sales, Opzelura sales and Hematology and Oncology sales. $INCY insiders have traded $INCY stock on the open market 12 times in the past 6 months. Of those trades, 0 have been purchases and 12 have been sales. Here's a breakdown of recent trading of $INCY stock by insiders over the last 6 months: To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint. We have seen 492 institutional investors add shares of $INCY stock to their portfolio, and 338 decrease their positions in their most recent quarter. Here are some of the largest recent moves: To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
